Nemtabrutinib, ACALABRUTINIB , Nemtabrutinib, IBRUTINIB
MK-1026-011
Phase 3 small_molecule active
Quick answer
Nemtabrutinib, ACALABRUTINIB , Nemtabrutinib, IBRUTINIB for Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL) is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active